Literature DB >> 7240955

Heterogeneity of serum low density lipoproteins in normal human subjects.

M M Shen, R M Krauss, F T Lindgren, T M Forte.   

Abstract

Equilibrium density gradient ultracentrifugation of serum low density lipoprotein (LDL) from twelve healthy human subjects was used to separate six subfractions with mean density ranging from 1.0268 to 1.0597 g/ml. Mean corrected peak flotation rate (Sof) measured by analytic ultracentrifugation, and mean particle diameter determined by negative staining electron microscopy, both declined significantly with increasing density of the subfractions. Major differences in chemical composition of the subfractions were noted, including a significantly lower triglyceride content and higher ratio of cholesteryl ester to triglyceride in the middle fractions compared with those of highest and lowest density. Concentration of fraction 2 correlated positively with HDL (P less than 0.01) and negatively with VLDL (P less than 0.001); concentration of fraction 4 correlated negatively with HDL (P less than 0.05) and positively with VLDL (P less than 0.001) and IDL (P less than 0.01). LDL may thus include subspecies of differing structure and composition which might also have different metabolic and atherogenic roles.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240955

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

Review 1.  LDL particle size: an important drug target?

Authors:  I Rajman; P I Eacho; P J Chowienczyk; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 2.  Small, dense low-density lipoprotein: risk or myth?

Authors:  Ngoc-Anh Le
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

3.  Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families.

Authors:  J de Graaf; D W Swinkels; A F de Haan; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

4.  Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.

Authors:  Thomas A Hughes; Frankie Stentz; Thomas Gettys; Steven R Smith
Journal:  Metabolism       Date:  2006-01       Impact factor: 8.694

5.  Multilocus genetic determinants of LDL particle size in coronary artery disease families.

Authors:  J I Rotter; X Bu; R M Cantor; C H Warden; J Brown; R J Gray; P J Blanche; R M Krauss; A J Lusis
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

6.  Reduced beta-strand content in apoprotein B-100 in smaller and denser low-density lipoprotein subclasses as probed by Fourier-transform infrared spectroscopy.

Authors:  F Tanfani; T Galeazzi; G Curatola; E Bertoli; G Ferretti
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

7.  Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits.

Authors:  N Yamada; H Shimano; H Mokuno; S Ishibashi; T Gotohda; M Kawakami; Y Watanabe; Y Akanuma; T Murase; F Takaku
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  Cryoelectron microscopy of low density lipoprotein in vitreous ice.

Authors:  J M Spin; D Atkinson
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

9.  Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.

Authors:  B Teng; G R Thompson; A D Sniderman; T M Forte; R M Krauss; P O Kwiterovich
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

10.  Lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients.

Authors:  E Manzato; A Zambon; S Zambon; R Nosadini; A Doria; R Marin; G Crepaldi
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.